Related Experiment Videos
P53 as a prognostic marker for bladder cancer: a meta-analysis and review
Núria Malats1, Aurelia Bustos, Cristiane M Nascimento
1Municipal Institute of Medical Investigation, Barcelona, Spain. nuria@imim.es
The Lancet. Oncology
|September 1, 2005
Summary
Evidence is insufficient to determine if P53 protein changes predict bladder cancer outcomes. Further research is needed to clarify the prognostic value of P53 in bladder cancer recurrence, progression, and mortality.
Area of Science:
- Oncology
- Molecular Biology
- Biomarkers
Background:
- P53 is a key molecular marker in bladder cancer research.
- Its role in predicting patient outcomes requires comprehensive evidence evaluation.
Purpose of the Study:
- To systematically review existing evidence on P53 changes as predictors of bladder cancer recurrence, progression, and mortality.
- To assess the prognostic significance of P53 in bladder cancer.
Main Methods:
- A meta-analysis of 117 studies (168 publications) was conducted.
- Data extracted included significance estimates, hazard ratios, and confidence intervals.
- Cox regression analyses and actuarial curves were utilized.
Main Results:
- Significant associations between P53 overexpression and outcomes varied by endpoint (recurrence 27%, progression 50%, mortality 29%).
- Meta-analysis using Cox models indicated increased risks: recurrence (1.6), progression (3.1), and mortality (1.4).
- Potential overestimation due to publication and reporting bias was noted.
Conclusions:
- After a decade of research, conclusive evidence is lacking.
- The utility of P53 changes as outcome markers in bladder cancer remains uncertain.